Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.
Yaseen M ArabiAyed Y AsiriAbdullah M AssiriHanan H BalkhyAli Al BshabsheMajed Al JeraisyYasser MandourahMohamed H A AzzamAbdulhadi M Bin EshaqSameera Al JohaniShmeylan Al HarbiHani A A JokhdarAhmad M DeebZiad A MemishJesna JoseSameeh GhazalSarah Al FarajGhaleb A Al MekhlafiNisreen M SherbeeniFatehi E ElzeinFahad Al-HameedAsim Al SaediNaif K AlharbiRobert A FowlerFrederick G HaydenAbdulaziz Al-DawoodMohamed AbdelzaherWail BajhmomBadriah M AlMutairiMohamed A HusseinAdel Alothmannull nullPublished in: The New England journal of medicine (2020)
A combination of recombinant interferon beta-1b and lopinavir-ritonavir led to lower mortality than placebo among patients who had been hospitalized with laboratory-confirmed MERS. The effect was greatest when treatment was started within 7 days after symptom onset. (Funded by the King Abdullah International Medical Research Center; MIRACLE ClinicalTrials.gov number, NCT02845843.).